According to the statement shared with stock exchanges by TIL, the quantum of funds to be invested by Gainwell Group wasn't mentioned.

The pharmaceutical firm's net revenue went down 3.4 per cent to Rs 5,739 crore against Rs 5,941 crore in the corresponding period the previous year. Net Ebitda of the company went down 33 per cent to Rs 790 crore against Rs 1,186 crore in the year-ago period.

On Friday, garbage was found littered open on New Town and Salt Lake streets in the city.

The residence and office of Managing Director of Manipur State Power Distribution Company N. Sarat Singh raided on Monday.

New Delhi [India], October 17 (ANI/PNN): Dr Raj Kishor Khaware and Utpaal Acharya represented the film studio while the Chief Secretary Tourism, Culture and Managing director tourism board, Shiv Shekhar Shukla, Managing Director of Tourism Development Corporation, S. Viswanathan and Upper Managing Director M. P. Tourism board, Vivek Shrotriya represented the tourism department of Madhya Pradesh government.

New Delhi [India], October 17 (ANI): Leading company of design-led technology services Tata Elxsi has announced a 39 per cent year-on-year growth in net profit at Rs174.30 crore for the quarter ended September 30, 2022.

New Delhi [India], October 15 (ANI): The Enforcement Directorate (ED) has attached properties worth Rs 1,317.30 crore belonging to real estate company IREO Pvt Ltd, its Managing Director cum Vice President Lalit Goyal, associated entities and key managerial persons, the agency said on Saturday.

Mumbai (Maharashtra) [India], August 3 (ANI): The Board of Directors of Vodafone Idea Limited on Wednesday decided to elevate its Managing Director and Chief Executive Officer Ravinder Takkar to the position of chairman effective from August 19.

New Delhi [India], June 16 (ANI): In the wake of rising prices of jet fuel and the depreciation of the Indian Rupee, India's low-cost airline SpiceJet on Thursday called for 10-15 per cent hikes in airfares to sustain the operation.

New Delhi Apr 26 PTI Bharat Biotech International Ltd BBIL on Tuesday said its COVID-19 vaccine Covaxin has received emergency use approval in children 6-12 years of age in India Earlier approved for children 12-18 years of age Covaxin has proven to be safe well-tolerated and immunogenic in paediatric subjects in phase IIIII study in children 2-18 years of age Bharat Biotech said in a statement The company said it conducted clinical trials in paediatric population between June 2021 to September 2021 and results have shown robust safety reactogenicity and immunogenicity The data readouts were submitted to the Central Drugs Standard Control Organisation CDSCO during October 2021 and received emergency use nod for children aged 12-18 from DCGI during December 2021 it added Bharat Biotech further said clinical trials in children documented seroconversion at 95-98 per cent four weeks after the second dose indicating superior antibody responses in children when compared to adults Commenting on the development Bharat Biotech Chairman and Managing Director Krishna Ella said We have established Covaxin as an universal vaccine for adults and children Safety of the vaccine is critical for children and we are glad to share that Covaxn has now proven data for safety and immunogenicity in children We have achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children The company said fresh stocks of Covaxin are available and ready for supplies It has readily available more than 5 crore doses of Covaxin in vials and more than 20 crore doses as drug substance Additional production capacity is also available to meet product demand it added Earlier this month Bharat Biotech had announced that it was temporarily slowing down production of Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement agencies and foresee decrease in demand The World Health Organization WHO had also confirmed the suspension of supply of Covaxin through UN procurement agencies and recommended countries that received the vaccine to take actions as appropriate WHO had said the suspension was in response to the outcome of WHO post Emergency Use Listing EUL inspection and the need to conduct process and facility upgrade to address identified GMP deficiencies The company after the WHO post Emergency Use Listing EUL inspection said it was working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements PTI RKL MR